Compare OVBC & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVBC | IPHA |
|---|---|---|
| Founded | 1872 | 1999 |
| Country | United States | France |
| Employees | N/A | 163 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.5M | 189.5M |
| IPO Year | 1996 | N/A |
| Metric | OVBC | IPHA |
|---|---|---|
| Price | $43.07 | $1.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | ★ 39.5K | 8.8K |
| Earning Date | 04-28-2026 | 03-26-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | ★ 42.67 | N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $180.36 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $46.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.61 | $1.18 |
| 52 Week High | $51.25 | $2.63 |
| Indicator | OVBC | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 36.80 | 51.21 |
| Support Level | $39.07 | $1.73 |
| Resistance Level | $45.64 | $1.80 |
| Average True Range (ATR) | 2.17 | 0.09 |
| MACD | -0.63 | -0.01 |
| Stochastic Oscillator | 13.55 | 27.60 |
Ohio Valley Banc Corporation is a financial holding company. The bank is a full-service financial institution offering a blend of commercial and consumer banking services in Southeastern Ohio and western West Virginia. The banking services offered by the bank include the acceptance of deposits in checking, savings, time and money market accounts; the making and servicing of personal, commercial, and student loans; and the making of construction and real estate loans. It also offers individual retirement accounts, safe deposit boxes, wire transfers, and other standard banking products and services.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.